HDAC9 and neuroendocrine neoplasm: Two decades of studies suggest that HDAC inhibition could be important in neuroendocrine neoplasms, from the observation of a patient with a pancreatic islet cell tumor with a response to romidepsin in a Phase I study, activity in small clinical trials, through numerous in vitro studies, and more recently, in key bioinformatics analyses [33,34,35,36,37,38].